Kevin Ali, Organon CEO
December 13, 2024 03:53 PM EST
Pharma
FDA+

Organon's steroid-free cream Vta­ma wins ap­proval in atopic der­mati­tis

Nicole DeFeudis

Editor

Organon won a la­bel ex­pan­sion on Fri­day for the steroid-free top­i­cal cream it picked up from its Oc­to­ber ac­qui­si­tion of Der­ma­vant.

Vta­ma, al­so known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

A service from the Financial Times